Posts Tagged ‘significantly’

Treatment With Prolia(R) (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence …

Treatment With Prolia(R) (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence …
Thousand Oaks, California (ots/PRNewswire) – Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia(R) (denosumab) treatment than during …

Read more on Presseportal

VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Major Vascular Events in Patients With Chronic Kidney Disease …

VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Major Vascular Events in Patients With Chronic Kidney Disease …
In a new investigational study of VYTORIN ® (ezetimibe/simvastatin), the cholesterol-lowering medicine from Merck (known as MSD outside the US and Canada), VYTORIN 10/20 mg reduced the incidence of first major vascular events — defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure — by a highly statistically significant 16.1 percent compared to placebo …

Read more on Finanzen.net

CyberKnife® VSI System Expands Treatment Applications and Significantly Reduces Treatment Times

CyberKnife® VSI System Expands Treatment Applications and Significantly Reduces Treatment Times
Accuray Incorporated , a global leader in the field of radiosurgery, announced today feedback from Creekside Cancer Care on their use of the CyberKnife VSI System. Â Creekside Cancer Care was the first facility in the world to install and begin treating patients with the CyberKnife VSI System. Â Patient treatments began in June 2010 and clinicians at Creekside Cancer Care quickly reported that …

Read more on PR Newswire via Yahoo! Finance

Novartis Gains FDA Approval For Gilenya™, A Novel First-Line Multiple Sclerosis Treatment Shown To Significantly …

Novartis Gains FDA Approval For Gilenya™, A Novel First-Line Multiple Sclerosis Treatment Shown To Significantly …
Today Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya™ (fingolimod) 0.5 mg daily, a first-line treatment for relapsing forms of multiple sclerosis – the most common forms of the disease.

Read more on PharmaceuticalOnline

Birth Control Pills Significantly Increase Breast Cancer Risk / Video

Best Preventative Action Against Breast Cancer / Video. Published by Secret of the Rosary Films. Image from Fair Use. CHICAGO, March 7, 2006 (LifeSiteNews.com) A world leader in cancer causes and prevention has warned that the so-called birth control pill is the largest unregulated human trial thats ever been conducted. Dr. Sam Epstein, author of Cancer-Gate: How to Win the Losing Cancer War and Professor of Environmental and Occupational Medicine at the School of Public Health, University of Illinois at Chicago, told the CBCs Marketplace that exposure to the hormones estrogen and progestin, as found in the pill, increase breast cancer risk. Marketplace author Wendy Mesley, herself a breast cancer survivor, explained that the World Health Organizations International Agency for Research on Cancer last year re-classified hormonal contraceptives as carcinogenic to humans. Dr. Chris Kahlenborn, MD demonstrated that a woman who takes birth control pills before her first child is born has at least a 40 percent increased risk of developing breast cancer and a woman who has taken the pill for four or more years prior to the birth of her first child has a 72 percent risk factor in developing breast cancer. Dr. Kahlenborns book, Breast cancer: Its link to abortion and the birth control pill, published by One More Soul, is based on six years of study and a meticulous analysis of hundreds of scientific papers and other sources. A European study, which looked at 103000 women aged …